Table 2.
Small compounds used to alter splicing events.
| Target | Compound | Mechanism | Reference |
|---|---|---|---|
| SF3B1 | Pladienolide E7107 | Abolish the conformation rearrangement of SF3B1 | 98 |
| Spliceostatins | 99 | ||
| Herboxidiene | 100,101 | ||
| U5 snRNP | Brr2 | Interfere with the RNA helicase activity | 102,103 |
| U2 snRNP | Sudemycin K | Inhibitor of spliceosome assembly | 104 |
| hnRNPA1 | VPC-80051 | Prevent AR-V7 generation and reduce c-Myc transcription output | 105 |
| SRSF10 | GPS167 | Increase the interaction of SRSF10 with the CLK1 and CLK4 kinases | 106 |
| SRRK family | SRPIN340 | ATP binding competitor | 107 |
| SRPKIN-1 | Convert the pro-angiogenic VEGF-A165a to the anti-angiogenic VEGF-A165b isoform | 108 | |
| ZINC02154892 (C02) | Binds to targeted ATP binding site and inhibits recruitment of ASF/SF2 by SRPK1 | 109 | |
| CLK family | TG-003; TG-693 | Interfere with ATP binding | 110 |
| CX-4945 | Phosphorylation of serine/arginine-rich proteins | 111 | |
| RECTAS | 112 | ||
| SM08502 | Inhibit SRSF phosphorylation and disrupted spliceosome activity | 113 |